Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: DNA Methylation Profiling of Glioblastoma: Impact on Gene Expression and Clinical Outcome (Agilent Expression Study)

OTHER RELATED OMICS DATASETS IN: E-GEOD-22866

PROVIDER: PRJNA129141 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

E-GEOD-22866

Project description:DNA Methylation Profiling of Glioblastoma: Impact on Gene Expression and Clinical Outcome (Agilent Expression Study)

2025-01-24 | E-GEOD-22866 | ExpressionAtlas

DNA Methylation Profiling of Glioblastoma: Impact on Gene Expression and Clinical Outcome

Project description:This SuperSeries is composed of the following subset Series: GSE22866: DNA Methylation Profiling of Glioblastoma: Impact on Gene Expression and Clinical Outcome (Agilent Expression Study) GSE22867: DNA Methylation Profiling of Glioblastoma: Impact on Gene Expression and Clinical Outcome (Illumina) Refer to individual Series

2011-06-29 | E-GEOD-22891 | biostudies-arrayexpress

DNA Methylation Profiling of Glioblastoma: Impact on Gene Expression and Clinical Outcome

Project description:DNA Methylation Profiling of Glioblastoma: Impact on Gene Expression and Clinical Outcome

| PRJNA128155 | ENA

Homo sapiens

Project description:DNA Methylation Profiling of Glioblastoma: Impact on Gene Expression and Clinical Outcome (Illumina)

| PRJNA129143 | ENA

E-GEOD-11166

Project description:Local regulation and clinical impact of complement gene expression in deceased and living donor kidney allografts

2025-01-16 | E-GEOD-11166 | ExpressionAtlas

E-GEOD-2198

Project description:Transcription profiling of muscles from mice with genetically modified muscle glycogen content to study the impact of glycogen content on gene expression.

2015-09-15 | E-GEOD-2198 | ExpressionAtlas

E-MTAB-3864

Project description:Expression profiling of normal and glioblastoma-derived neural stem cells

2025-01-23 | E-MTAB-3864 | ExpressionAtlas

E-MTAB-1311

Project description:Transcription profiling by array of rat normal bronchial epithelial cells to study the impact of TNFa on NFkB translocation and gene expression pattern

2015-10-23 | E-MTAB-1311 | ExpressionAtlas

The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma

Project description:Glioblastoma is the most common malignant primary brain tumor. Clinically relevant biomarkers are restricted to isocitrate dehydrogenase (IDH) gene 1 or 2 mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Long non-coding RNA (lncRNA) alterations may contribute to glioblastoma pathogenesis and potentially serve as novel biomarkers. The clinical significance of HOXA Transcript Antisense RNA, Myeloid-Specific 1 (HOTAIRM1) was analyzed in multiple glioblastoma gene expression data sets for associations with prognosis and IDH mutation and MGMT promoter methylation status. The role of HOTAIRM1 in glioblastoma biology and radiotherapy resistance was characterized in vitro and in vivo. We identified HOTAIRM1 as a candidate lncRNA whose up-regulation is significantly associated with shorter survival of glioblastoma patients independent from IDH mutation and MGMT promoter methylation. Glioblastoma cell line models uniformly showed reduced cell viability, less invasive growth and diminished colony formation capacity upon HOTAIRM1 down-regulation. Integrated proteogenomic analyses and determination of reactive oxygen species (ROS) levels revealed impaired mitochondrial function and increased ROS levels upon HOTAIRM1 knock-down. HOTAIRM1 knock-down decreased expression of transglutaminase 2 (TGM2) as a candidate protein implicated in mitochondrial function, and knock-down of TGM2 mimicked the phenotype of HOTAIRM1 down-regulation in glioblastoma cells. Moreover, HOTAIRM1 modulates radiosensitivity of glioblastoma cells in vitro and in vivo. Our data support a role for HOTAIRM1 as a driver of biological aggressiveness, radioresistance and poor outcome in glioblastoma. Targeting HOTAIRM1 may be a promising new therapeutic approach.

2022-01-19 | PXD020141 | Pride

A novel six-CpGs signature predicts clinical outcome in glioblastomas

Project description:We aimed to identify a clinically useful biomarker using DNA methylation-based information to optimize the management of glioblastoma (GBM) patients. We identified a novel six-CpGs signature that predicts the clinical outcome in GBM. The methylation profiling of 79 GBM patients has been used as a validation cohort to demonstrate the performance and the robustness of the identified six-CpGs signature. The status of the âMGMTâ biomarker, traditionally used by clinicians to predict survival in GBM, is also indicated per sample.

2017-12-15 | E-MTAB-4969 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data